Is Reglan (metoclopramide) classified as an antipsychotic medication?

Reglan (Metoclopramide) Is NOT Classified as an Antipsychotic Medication

Reglan (metoclopramide) is a dopamine receptor antagonist used primarily as a prokinetic agent and antiemetic—it is NOT classified or approved as an antipsychotic medication, despite sharing some pharmacological mechanisms with antipsychotic drugs. 1

Pharmacological Classification and Mechanism

Metoclopramide is classified as a substituted benzamide derivative with the following properties:

• Primary mechanism: Dopamine D2 receptor antagonist
• Additional actions: 5-HT3 receptor antagonist and 5-HT4 receptor agonist
• Structural similarity: Related to procainamide and sulpiride (not typical antipsychotics) 2, 3

While metoclopramide does antagonize dopamine receptors (a mechanism shared with antipsychotics), this does not make it an antipsychotic medication. The drug's dopamine antagonism is utilized for gastrointestinal motility enhancement and antiemetic effects, not for treating psychotic disorders.

FDA-Approved Indications

According to the FDA drug label, metoclopramide is approved for 1:

• Gastroesophageal reflux disease (GERD): 4-12 weeks of treatment for heartburn symptoms when other treatments fail
• Diabetic gastroparesis: Relief of symptoms including nausea, vomiting, and delayed gastric emptying
• Chemotherapy-induced nausea and vomiting (parenteral formulation)

Metoclopramide is the only FDA-approved medication specifically for gastroparesis 4, 5. It is NOT approved for any psychiatric or psychotic disorder.

Clinical Use Context

Guidelines consistently position metoclopramide as:

• A prokinetic agent for gastric emptying 4, 5
• An adjunctive antiemetic for migraine-associated nausea 6
• A second-line antiemetic (after ondansetron) due to extrapyramidal side effect risks 7

The 2022 AGA gastroparesis guideline lists metoclopramide under "Medications to accelerate gastric emptying," not among antipsychotic medications 4. Similarly, the 2002 migraine guideline describes metoclopramide's "main use is for treating accompanying nausea," not as a primary therapeutic agent for psychiatric conditions 6.

Why the Confusion Exists

The confusion arises because metoclopramide:

1. Shares dopamine antagonist properties with antipsychotic drugs 2, 8
2. Can cause antipsychotic-like side effects: extrapyramidal symptoms, tardive dyskinesia, neuroleptic malignant syndrome 9, 1
3. Has been studied for antipsychotic properties in research settings 2, 10, but these remain investigational and are NOT part of clinical practice

One 1980 study noted metoclopramide displays "classic neuroleptic dopamine antagonist properties" in animal models and found it had "antipsychotic efficacy" at high doses 2. However, this research finding has never translated into clinical approval or guideline-recommended use as an antipsychotic.

Critical Safety Distinction

The FDA explicitly warns about tardive dyskinesia risk with metoclopramide 1:

• Black box warning for tardive dyskinesia (TD)
• Risk increases with: duration >12 weeks, higher doses, elderly patients (especially women), diabetics
• TD may be irreversible even after stopping the drug
• Maximum recommended duration: 12 weeks

The 2024 pregnancy guideline emphasizes: "Due to the risk of extrapyramidal effects with metoclopramide it should be used as second-line therapy" with maximum 5-day duration per European Medicines Agency recommendations (though longer use may be appropriate in some cases) 7.

The actual risk of tardive dyskinesia is approximately 0.1% per 1000 patient-years 3, far lower than the 1-10% previously estimated, but the risk remains real and limits long-term use.

Antipsychotic Guidelines Do Not Include Metoclopramide

Notably, comprehensive antipsychotic treatment guidelines make no mention of metoclopramide:

• The 2020 APA schizophrenia guideline lists haloperidol, chlorpromazine, risperidone, olanzapine, quetiapine, aripiprazole, and clozapine as antipsychotics 11
• The 2025 INTEGRATE international schizophrenia guidelines similarly exclude metoclopramide 12
• WHO guidelines on antipsychotic use list only traditional antipsychotics 13

When guidelines discuss phenothiazine antipsychotics like prochlorperazine and chlorpromazine for nausea in gastroparesis, they are listed separately from metoclopramide 4.

Clinical Bottom Line

Do not prescribe or refer to metoclopramide as an antipsychotic. It is a gastrointestinal medication with dopamine antagonist properties that happens to cause antipsychotic-like side effects. Using it for psychiatric indications would be:

• Off-label and unsupported by guidelines
• Potentially dangerous given TD risk without psychiatric benefit
• Inappropriate given availability of actual FDA-approved antipsychotics

If a patient needs treatment for psychotic symptoms, prescribe an actual antipsychotic medication (haloperidol, risperidone, olanzapine, etc.) 11, 12. If a patient needs treatment for gastroparesis or nausea, metoclopramide may be appropriate for short-term use (≤12 weeks) at the lowest effective dose 4, 5, 1.